These results highlight the utility of patient-derived models of FGFR2 fusion-positive ICC to investigate standard-of-care anti-cancer treatment and discover therapeutic strategies for this nearly universally deadly disease. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.